Amarin Corp Plc (AMRN)

[Notademoc]

April 26 (Reuters) - The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

The FDA's decision will allow the drug, developed along with Sanofi SA, to be prescribed to reduce the overall risk of major adverse cardiovascular events (MACE).

MACE includes heart attack, ischemic stroke, coronary heart disease and unstable chest pains requiring hospitalization.

Praluent belongs to a class of injectable biotech drugs called PCSK9 inhibitors that dramatically lower bad LDL cholesterol and reduce the risk of heart attacks and death.